Limb-sparing options for osteosarcoma-diagnosed dogs to be exploredJuly 28, 2022The Morris Animal Foundation-funded project will investigate limb-sparing options for large- and giant-breed dogs diagnosed with osteosarcoma. Ultimately, researchers hope to advance the treatment of and improve the prognosis for dogs receiving radiation treatment for this type of cancer.
SPONSORED CONTENTThey love them soYou know pet owners want to make sure they’re protected everywhere they go. + Learn more
Technicians are tops: The changing role of this critical team memberOctober 12, 2020It’s National Veterinary Technician Week, a time when we honor these tireless professionals who have never been more critical to animal health than over the last eight months or so.
Osteosarcoma in dogs and children genetically similarJuly 26, 2019The veterinary community might soon see advancements in the treatment of canine osteosarcoma (OS).
Osteosarcoma: Beyond amputation and euthanasiaMarch 12, 2019When a patient is diagnosed with osteosarcoma, we tend to focus on three options: • the “gold standard,” i.e. amputation with or without chemotherapy; • what many call palliative care, meaning pain medication and rest; or • euthanasia. But what if amputation is not an option? What if chemotherapy or radiation is out of the owner’s financial capabilities? Or a couple of medications are not enough to numb the pain? What if …
The race to develop immunotherapies for canine lymphoma and osteosarcomaJanuary 2, 2019There are many reasons why development of immunotherapies in dogs has been slow. Although cancer, and in particular lymphoma and osteosarcoma, is frequent in dogs, just one percent of owners have pet insurance; those who don’t are willing to spend only a limited amount of money to treat their dog, especially when initial treatment results are not as dramatic as in humans.
20-plus clinics to participate in expanded osteosarcoma vaccine clinical trialSeptember 6, 2018Initial results of a pilot study for canine osteosarcoma vaccine are promising, prompting a larger study to test its safety and efficacy. Pharmaceutical company Aratana Therapeutics, which received conditional licensure for Live Listeria Vector (AT-014), has expanded its clinical trial to include more than two dozen veterinary oncology practice groups across the U.S. in order to receive full licensure. Conducted by the University of Pennsylvania School of Veterinary Medicine, the pilot study tested the immunotherapy …
ELIAS presents preliminary canine osteosarcoma results at ACVIMAugust 3, 2018During the 2018 American College of Veterinary Internal Medicine Forum in June, ELIAS Animal Health, a clinical stage development company advancing novel treatments for companion animal cancer, shared preliminary canine osteosarcoma results for its cancer immunotherapy. According to study results presented by Brian Flesner, DVM, DACVIM (Oncology), University of Missouri, the company’s new ELIAS autologous cancer vaccine, featuring a patented vaccine and T cell infusion combination approach, demonstrated “impressive survival times and minimal side …
Canadian researchers team up to fight canine osteosarcomaJune 14, 2018A group of researchers called the Dog Osteosarcoma Group–Biomarkers of Neoplasia (DOGBONe) at the University of Guelph in Ontario, Canada, have joined forces to determine more accurate ways of measuring bone cancer, with the main objective of identifying biomarkers to assess patients with canine osteosarcoma. The presentation of osteosarcoma in dogs is remarkably similar to that of humans, according to the Ontario Veterinary College (OVC); so much so that computers are unable to distinguish …
MAF awards Penn $775K to test osteosarcoma immunotherapy vaccine in dogsApril 20, 2018Morris Animal Foundation (MAF) has awarded a $775,000 grant to the University of Pennsylvania to test a vaccine that could improve longevity and quality of life for dogs with osteosarcoma. The research team will conduct clinical trials to evaluate a novel immunotherapy treatment that combines a molecule expressed by cancer cells with a modified live form of Listeria monocytogenes. A pilot study demonstrated this combination elicited a powerful, targeted immune response directed …
Aratana Therapeutics secures USDA conditional license for canine osteosarcoma vaccineJanuary 10, 2018Aratana Therapeutics announced that its canine osteosarcoma vaccine, Live Listeria Vector (AT-014), has been granted a conditional license by the USDA Center for Veterinary Biologics for the treatment of dogs diagnosed with osteosarcoma, 1 year of age or older. The vaccine is a novel immunotherapy developed by using a listeria-based antigen delivery system licensed from Advaxis Inc. “Osteosarcoma is the most common primary bone tumor in dogs and, …